Healthcare firms perform well in subdued US IPO market in 2024 BioAge's azelaprag is being developed in combination with GLP-1 drugs Proceeds from IPO to advance azelaprag into late-stage studies ...
Obesity drug developer BioAge Labs (BIOA) has filed regulatory filings as part of its U.S. IPO. It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at ...
BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a ...
Aunque puedas pensar que no son necesarias, lo cierto es que ninguna rutina facial debería prescindir de una buena crema de noche. Estos tratamientos están diseñados específicamente para ...
(Reuters) - Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a ...
(Reuters) - Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory ...
Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...
Se usan en productos como limpiadores faciales y tratamientos antiinflamatorios, como el gel de aloe vera, que es conocido por sus propiedades calmantes y cicatrizantes. Ungüento: es un producto ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback